These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 11772291

  • 1. Neuroprotection for Parkinson's disease: a new approach for a new millennium.
    Drukarch B, van Muiswinkel FL.
    Expert Opin Investig Drugs; 2001 Oct; 10(10):1855-68. PubMed ID: 11772291
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Neuroprotective strategies in Parkinson's disease : an update on progress.
    Mandel S, Grünblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB.
    CNS Drugs; 2003 Oct; 17(10):729-62. PubMed ID: 12873156
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM, Altar CA, Cedarbaum JM, Hyman C, Wiegand SJ.
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [Abstract] [Full Text] [Related]

  • 9. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD, Jankovic J.
    Drugs Aging; 2001 Nov; 18(6):389-96. PubMed ID: 11419913
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. New pharmacologic horizons in the treatment of Parkinson disease.
    Bonuccelli U, Del Dotto P.
    Neurology; 2006 Oct 10; 67(7 Suppl 2):S30-8. PubMed ID: 17030738
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?
    Barzilai A, Melamed E, Shirvan A.
    Cell Mol Neurobiol; 2001 Jun 10; 21(3):215-35. PubMed ID: 11569535
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD, Aguiar AS, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman-Vozari R.
    Curr Pharm Des; 2011 Jun 10; 17(5):489-507. PubMed ID: 21375482
    [Abstract] [Full Text] [Related]

  • 16. Neuroinflammation in Parkinson's disease: a target for neuroprotection?
    Hirsch EC, Hunot S.
    Lancet Neurol; 2009 Apr 10; 8(4):382-97. PubMed ID: 19296921
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Where do we stand on neuroprotection? Where do we go from here?
    Shoulson I.
    Mov Disord; 1998 Apr 10; 13 Suppl 1():46-8. PubMed ID: 9613718
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.